Primary hyperparathyroidism with concurrent primary aldosteronism

Hypertension

Volumn 58, Issue 3, 2011, Pages 341-346

  Maniero, Carmela ^a   Fassina, Ambrogio ^b   Guzzardo, Vincenza ^b   Lenzini, Livia ^a   Amadori, Giuseppe ^a   Pelizzo, Maria Rosa ^c   Gomez Sanchez, Celso ^d   Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Department of Surgical Pathology ^*  (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; ATENOLOL; CALCIUM; CANRENOATE POTASSIUM; CAPTOPRIL; DOXAZOSIN; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID RECEPTOR; PARATHYROID HORMONE RECEPTOR 1; POTASSIUM; TELMISARTAN;

ADRENALECTOMY; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; GENE EXPRESSION PROFILING; HEART LEFT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; MALE; OPHTHALMOSCOPY; PARATHYROID ADENOMA; PARATHYROID SCINTISCANNING; PARATHYROIDECTOMY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RETINOPATHY; THORAX PAIN; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; AGED; HUMANS; HYPERALDOSTERONISM; HYPERPARATHYROIDISM, PRIMARY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; PARATHYROID HORMONE; RECEPTOR, PARATHYROID HORMONE, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80051919101     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.173948     Document Type: Article

References (32)

1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, for the PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006; 48:2293-2300. (Pubitemid 44873058)
2. Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med. 2002;251: 476-483. (Pubitemid 34537310)
3. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003;27:216-222. (Pubitemid 36926340)
4. Barenbrock M, Hausberg M, Kosch M, Kisters K, Rahn KH. Relation between calcium phosphate metabolism and flow-mediated vasodilation of the brachial artery in patients after renal transplantation. Trace Elem Elec. 1998;15:168-172. (Pubitemid 28474716)
5. Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res. 2011;34: 286-288.
6. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001;280:E209-E213.
7. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA, Giulini SM, Agabiti-Rosei E, Pessina AC. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51:1366-1371. (Pubitemid 351555951)
8. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001;86:1083-1090. (Pubitemid 32322986)
9. Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009;94:2437-2445.
10. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010;24:355-370.
11. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, for the American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
12. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404. (Pubitemid 35469393)
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
14. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
15. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
16. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921-1926. (Pubitemid 351778191)
17. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM, Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
18. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F, for the Primary Aldosteronism Prevalence in Italy Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension. 2007;50:424-431. (Pubitemid 47205795)
19. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens. 1998;5(suppl):S103-S106.
20. Rossi GP. Diagnosis and treatment of primary aldosteronism. Endocrinol Metab Clin North Am. 2011;40:313-332.
21. Grim CE. Evolution of diagnostic criteria for primary aldosteronism: Why is it more common in "drug-resistant" hypertension today? Curr Hypertens Rep. 2004;6:485-492. (Pubitemid 39600105)
22. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the control of plasma aldosterone concentration in normal man: I-response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest. 1972;51:1731-1742.
23. Luetscher JA, Weinberger MH, Dowdy AJ, Nokes GW, Balikian H, Brodie A, Willoughby S. Effects of sodium loading, sodium depletion and posture on plasma aldosterone concentration and renin activity in hypertensive patients. J Clin Endocrinol Metab. 1969;29:1310-1318.
24. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 1998;280: 69-77. (Pubitemid 28169082)
25. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
26. Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol. 1987;112:431-437. (Pubitemid 17020880)
27. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-878. (Pubitemid 40279888)
28. Ackermann D, Gresko N, Carrel M, Loffing-Cueni D, Habermehl D, Gomez-Sanchez C, Rossier BC, Loffing J. In vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: differential effect of corticosteroids along the distal tubule. Am J Physiol Renal Physiol. 2010;299:F1473-F1485.
29. Hernandez-Diaz I, Giraldez T, Arnau MR, Smits VA, Jaisser F, Farman N, Alvarez de la Rosa D. The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology. 2010;151:3888-3899.
30. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007; 5:e012.
31. Rosa J, Raska I Jr, Wichterle D, Petrak O, Strauch B, Somloova Z, Zelinka T, Holaj R, Widimsky J Jr. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res. 2011; 34:296-300.
32. Rizk-Rabin M, Assie G, Rene-Corail F, Perlemoine K, Hamzaoui H, Tissier F, Lieberherr M, Bertagna X, Bertherat J, Bouizar Z. Differential expression of parathyroid hormone-related protein in adrenocortical tumors: autocrine/paracrine effects on the growth and signaling pathways in H295R cells. Cancer Epidemiol Biomarkers Prev. 2008;17:2275-2285.